|
Coral Laboratories Limited has been promoted by Navin B Doshi of the DWD group. The Company is spearheaded by Kishor R Mehta as Executive Director. CLL produces various pharmaceutical formulations. To Manufacture pharmaceutical formulations like tablets,capsules the company went into public issue in March 94 at a total cost of Rs.2.5 crores. The project has been completed successfully CLL plans to expand its activities in the present premises by foraying into the sophisticated FFS (form fill and seal) technology for injections. The machinery for the said technology will be imported. The Coral group is also diversifying into housing construction and financial services for which a new company, Coral India Finance and Housing, will be incorporated. During the year 1999-2000, the company has received ISO-9002 Certification. |
Coral Laboratories Ltd.
| BSE: 524506 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE683E01017 |
| BSE 13:10 | 27 Oct | 359.00 |
-12.15 (-3.27%) |
OPEN
373.65 |
HIGH
373.65 |
LOW
353.00 |
| NSE 05:30 | 01 Jan | Coral Laboratories Ltd |
| OPEN | 373.65 |
| PREVIOUS CLOSE | 371.15 |
| VOLUME | 3863 |
| 52-Week high | 443.30 |
| 52-Week low | 81.20 |
| P/E | 10.67 |
| Mkt Cap.(Rs cr) | 128 |
| Buy Price | 359.00 |
| Buy Qty | 15.00 |
| Sell Price | 364.75 |
| Sell Qty | 5.00 |
Coral Laboratories Ltd. (CORALLABS) - Company History
Quick Links for Coral Laboratories:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
